-
Innovation Ranking
Innovation Ranking – Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings Inc (Matinas BioPharma) is a biopharmaceutical company that discovers and develops anti-infectives for orphan indications. The company develops lipid nanocrystal (LNC) technology, a drug delivery platform to deliver various molecules such as small molecules, proteins, peptides, oligonucleotides, vaccines, and gene editing technologies. Its pipeline products include MAT2203, an LNC formulation of amphotericin B used for the prevention of IFI in acute lymphoblastic leukemia; and MAT2501, an LNC formulation of amikacin used for non-tuberculosis mycobacterium infections. The company...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Ulcerative Colitis Drug Details: Ustekinumab biosimilar (SB17) is...
-
Product Insights
Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Candidiasis - Drugs In Development, 2023’, provides an overview of the Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Aspergillosis - Drugs In Development, 2023’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Vulvovaginal Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvovaginal Candidiasis - Drugs In Development, 2023’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Zygomycosis (Mucormycosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Zygomycosis (Mucormycosis) - Drugs In Development, 2023’, provides an overview of the Zygomycosis (Mucormycosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zygomycosis (Mucormycosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cryptococcal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cryptococcal Meningitis - Drugs In Development, 2023’, provides an overview of the Cryptococcal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryptococcal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fungal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Fungal Meningitis - Drugs In Development, 2023’, provides an overview of the Fungal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fungal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Systemic Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Candidiasis - Drugs In Development, 2023’, provides an overview of the Systemic Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...